Drug
Ivosidenib clinical trials
Also written AG-120 and Tibsovo.
Keep track of what changes. Save the ivosidenib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
54 studies that test it; most in 2024 (8); 1 more planned to start later
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 8 |
| 2025 | 3 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 41
Institut de Recherches Internationales Servier (8) · Agios Pharmaceuticals, Inc. (5) · M.D. Anderson Cancer Center (4) · Memorial Sloan Kettering Cancer Center (3) · Servier Bio-Innovation LLC (3) · Institute of Hematology & Blood Diseases Hospital, China (3) · Servier Affaires Médicales (2) · National Cancer Institute (NCI) (2)
Often tested with
Tested in the same studies.
Azacitidine (10) · Enasidenib (8) · Venetoclax (8) · Daunorubicin (4) · Gilteritinib (4) · Idarubicin (3) · Nivolumab (3) · Cytarabine (3)
Studies
Open first, then newest update. How each study uses ivosidenib is read from its arms, and is right about nine times in ten.
Testing it · 55
- Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment RegimenRecruitingPhase 3Servier Bio-Innovation LLCNCT06127407Written as Ivosidenib 500mg
- Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionRecruitingPhase 1M.D. Anderson Cancer CenterNCT05010772Written as Ivosidenib
- A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid LeukemiaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07392242Written as Ivosidenib
- Ivosidenib as Post-HSCT Maintenance for AMLRecruitingPhase 2Massachusetts General HospitalNCT06707493Written as Ivosidenib
- Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML PatientsRecruitingPhase 2PETHEMA FoundationNCT07507760Written as Ivosidenib Oral Tablet
- Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT03471260Written as Ivosidenib
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as AG-120 (BAML-16-001-S16)
- Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 MutationRecruitingPhase 3Institut de Recherches Internationales ServierNCT06465953Written as Ivosidenib
- Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene MutationRecruitingPhase 1University of ChicagoNCT06291987Written as Ivosidenib
- Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) MutationRecruitingPhase 2Technische Universität DresdenNCT06717958Written as Ivosidenib 250 MG (milligram)
- CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 2M.D. Anderson Cancer CenterNCT04493164Written as Ivosidenib
- Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT07260175Written as Ivosidenib
- MRD-positive AML Clinical StudyRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07131059Written as Ivosidenib
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06265545Written as Ivosidenib
- A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentRecruitingPhase 1Servier Bio-Innovation LLCNCT07006688Written as Ivosidenib Oral Tablet
- Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerNot yet recruitingPhase 3UNICANCERNCT07745296Written as Ivosidenib + Capecitabine
- IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)RecruitingPhase 2Alice MimsNCT05401097Written as Ivosidenib
- Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationRecruitingPhase 1Institut de Recherches Internationales ServierNCT02074839Written as AG-120
- Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDSRecruitingPhase 2Ruijin HospitalNCT07607418Written as Ivosidenib
- Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT04774393Written as Ivosidenib
See all 55 studies that test ivosidenib →
Given in every arm · 4 — ivosidenib is usual care beside what is tested
- Study of SA+X in the Treatment of Newly Diagnosed AMLRecruitingPhase 2Ruijin HospitalNCT07548710Written as Ivosidenib
- An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.RecruitingPhase 2Peking Union Medical College HospitalNCT07282262Written as Ivosidenib
- A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative NeoplasmsWithdrawnPhase 1University of ChicagoNCT04955938Written as Ivosidenib
- Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationWithdrawnPhase 1City of Hope Medical CenterNCT04655391Written as Ivosidenib
Codes
What other systems call ivosidenib · ClinicalTrials.gg INT000950
- MeSH (NLM) C000627630ivosidenibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Q2PCN8MAM6IVOSIDENIBConfirmed FDA, NLM, Wikidata
- RxNorm 2049873One source FDA
- Wikidata Q27895417ivosidenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C114383IvosidenibOne source FDA
- DrugBank DB14568One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627630 | ivosidenib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Q2PCN8MAM6 | IVOSIDENIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2049873 | — | One source FDA |
| Wikidata | Q27895417 | ivosidenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C114383 | Ivosidenib | One source FDA |
| DrugBank | DB14568 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.